IMRX — Immuneering Share Price
Last trade - 00:00- $348.72m
- $192.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.69 | ||
| Price to Tang. Book | 1.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.23% | ||
| Return on Equity | -43.84% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.08 | 0.32 | n/a | n/a | n/a | n/a | 16 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Directors
- Robert Carpenter NEC (76)
- Benjamin Zeskind PRE (39)
- Biren Amin CFO (48)
- Brett Hall CSO (53)
- Kevin Flower VPR
- Michael Bookman GCN (34)
- Scott Barrett OTH (58)
- Rebecca Kusko OTH
- Diana Hausman DRC
- Ann Berman IND (69)
- Peter Feinberg IND (61)
- Laurie Keating IND (67)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- February 14th, 2008
- Public Since
- July 30th, 2021
- No. of Shareholders
- 60
- No. of Employees
- 55
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 64,697,402
- Address
- 245 Main Street, Second Floor, CAMBRIDGE, 02142
- Web
- https://immuneering.com/
- Phone
- +1 3026587581
- Auditors
- RSM US LLP
Upcoming Events for IMRX
Similar to IMRX
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
As of Today at 21:15 UTC, shares in Immuneering are trading at $5.39. This share price information is delayed by 15 minutes.
Shares in Immuneering last closed at $5.39 and the price had moved by +271.72% over the past 365 days. In terms of relative price strength the Immuneering share price has outperformed the S&P500 Index by +188.63% over the past year.
The overall consensus recommendation for Immuneering is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreImmuneering does not currently pay a dividend.
Immuneering does not currently pay a dividend.
Immuneering does not currently pay a dividend.
To buy shares in Immuneering you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.39, shares in Immuneering had a market capitalisation of $348.72m.
Here are the trading details for Immuneering:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: IMRX
Based on an overall assessment of its quality, value and momentum Immuneering is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Immuneering is $17.00. That is 215.4% above the last closing price of $5.39.
Analysts covering Immuneering currently have a consensus Earnings Per Share (EPS) forecast of -$1.15 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immuneering. Over the past six months, its share price has underperformed the S&P500 Index by -33.76%.
As of the last closing price of $5.39, shares in Immuneering were trading -6.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Immuneering PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.39.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Immuneering's management team is headed by:
- Robert Carpenter - NEC
- Benjamin Zeskind - PRE
- Biren Amin - CFO
- Brett Hall - CSO
- Kevin Flower - VPR
- Michael Bookman - GCN
- Scott Barrett - OTH
- Rebecca Kusko - OTH
- Diana Hausman - DRC
- Ann Berman - IND
- Peter Feinberg - IND
- Laurie Keating - IND